This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2000 Mar 18;355(9208):944-5.

doi: 10.1016/S0140-6736(00)90007-2.

Where next with stem-cell-supported high-dose therapy for breast cancer?

J Bergh¹

Affiliations

PMID: 10768427
DOI: 10.1016/S0140-6736(00)90007-2

Comment

Where next with stem-cell-supported high-dose therapy for breast cancer?

J Bergh. Lancet. 2000.

. 2000 Mar 18;355(9208):944-5.

doi: 10.1016/S0140-6736(00)90007-2.

Author

J Bergh¹

Affiliation

¹ Radiumhemmet and Cancer Centre Karolinska, Karolinska Institute and Hospital, Stockholm, Sweden.

PMID: 10768427
DOI: 10.1016/S0140-6736(00)90007-2

No abstract available

PubMed Disclaimer

Comment in

High-dose chemotherapy for breast cancer.
Bearman SI. Bearman SI. Lancet. 2000 Aug 12;356(9229):595-6. doi: 10.1016/S0140-6736(05)73975-1. Lancet. 2000. PMID: 10950259 No abstract available.

Comment on

High-dose chemotherapy for high-risk primary breast cancer: an on-site review of the Bezwoda study.
Weiss RB, Rifkin RM, Stewart FM, Theriault RL, Williams LA, Herman AA, Beveridge RA. Weiss RB, et al. Lancet. 2000 Mar 18;355(9208):999-1003. doi: 10.1016/S0140-6736(00)90024-2. Lancet. 2000. PMID: 10768448 Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information